High-content screening

Product Name Product Description Specification
SL#003 Wnt/β-catenin Pathway Inhibitors
Release: 04/16/2016

Wnt cascade is mis-regulated in many human malignancies including 90% of colon cancers; therefore, blocking of Wnt signaling is considered an attractive therapeutic approach for colorectal cancer treatment [1,2].

In library: WNT pathway inhibitors
SL#012 Wnt/β-catenin Pathway Activators
Release: 05/06/2016

Re-activation of the Wnt/β-catenin pathway is essential for the regeneration of many tissues such as liver, brain, muscle, skin, and bone. Many publications suggest that Wnt pathway agonists or activators are desirable candidates for regeneration-enhancing therapies [1].

In library: WNT pathway activators
SL#013 Gram negative Antibacterials
Release: 05/08/2016

Drug resistance has created a need for new antibiotic discovery, development, and approval. This is especially true of Gram-negative bacterial pathogens as the problem has escalated over the past few years [1].

In library: Phenotypic antibacterial
SL#024 STAT-3 inhibitors
Release: 06/21/2016

STAT3 signaling is frequently activated in malignant cells leading to over-expression and accumulation of anti-apoptotic proteins. [1]. STAT3 is the lowest point of fusion of many signaling pathways, thus providing an attractive target for therapeutic intervention in the treatment of cancer [2].

In library: STAT3 pathway inhibitors
SL#048 ApoE activators
Release: 08/22/2016
In library: High-content screening
SL#049 SMO inhibitors
Release: 08/25/2016
In library: High-content screening